Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration

nork Martell, Robert E., Sermer, David, Getz, Kenneth, Kaitin, Kenneth I.
Argitaratua 2013

Cost sharing for breast cancer hormone therapy: How do dual eligible patients’ copayment impact adherence

nork Ma, Siyu, Shepard, Donald S., Ritter, Grant A., Martell, Robert E., Thomas, Cindy Parks
Argitaratua izan da PLoS One (2021)

Metformin, diabetes, and survival among US veterans with colorectal cancer

nork Paulus, Jessica K., Williams, Christina D., Cossor, Furha I., Kelley, Michael J., Martell, Robert E.
Argitaratua izan da Cancer Epidemiol Biomarkers Prev (2016)

Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer – Response to Letter

nork Paulus, Jessica K., Williams, Christina D., Cossor, Furha I., Kelley, Michael J., Martell, Robert E.
Argitaratua izan da Cancer Epidemiol Biomarkers Prev (2017)

Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies

nork Godara, Amandeep, Siddiqui, Nauman S., Hachem, Hilal, Tsichlis, Philip N., Martell, Robert E., Saif, Muhammad Wasif
Argitaratua izan da J Cell Signal (2020)

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

nork Buglio, Daniela, Mamidipudi, Vidya, Khaskhely, Noor M., Brady, Helen, Heise, Carla, Besterman, Jeffrey, Martell, Robert E., MacBeth, Kyle, Younes, Anas
Argitaratua 2010

EVALUATION OF THE PHARMACODYNAMIC EFFECTS OF MGCD0103 FROM PRECLINICAL MODELS TO HUMAN, USING A NOVEL HDAC ENZYME ASSAY

nork Bonfils, Claire, Kalita, Ann, Dubay, Marja, Siu, Lillian L., Carducci, Michael A., Reid, Gregory, Martell, Robert E., Besterman, Jeffrey M., Li, Zuomei
Argitaratua 2008

Diabetes, Metformin Use, and Colorectal Cancer Survival in Postmenopausal Women

nork Cossor, Furha Iram, Adams-Campbell, Lucile L., Chlebowski, Rowan T., Gunter, Marc J, Johnson, Karen, Martell, Robert E., McTiernan, Anne, Simon, Michael S., Rohan, Thomas, Wallace, Robert B., Paulus, Jessica K.
Argitaratua 2013

Phase II Study of the Histone Deacetylase Inhibitor MGCD0103 in Patients with Previously Treated Chronic Lymphocytic Leukemia

nork Blum, Kristie A., Advani, Anjani, Fernandez, Louis, Van Der Jagt, Richard, Brandwein, Joseph, Kambhampati, Suman, Kassis, Jeannine, Davis, Melanie, Bonfils, Claire, Dubay, Marja, Dumouchel, Julie, Drouin, Michel, Lucas, David M., Martell, Robert E., Byrd, John C.
Argitaratua 2009

Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma

nork Younes, Anas, Oki, Yasuhiro, Bociek, R. Gregory, Kuruvilla, John, Fanale, Michelle, Neelapu, Sattva, Copeland, Amanda, Buglio, Daniela, Galal, Ahmed, Besterman, Jeffrey, Li, Zuomei, Drouin, Michel, Patterson, Tracy, Ward, M. Renee, Paulus, Jessica K., Ji, Yuan, Medeiros, L. Jeffrey, Martell, Robert E.
Argitaratua izan da Lancet Oncol (2011)

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

nork Siu, Lillian L., Pili, Roberto, Duran, Ignacio, Messersmith, Wells A., Chen, Eric X., Sullivan, Rana, MacLean, Martha, King, Serina, Brown, Shirley, Reid, Gregory K., Li, Zuomei, Kalita, Ann M., Laille, Eric J., Besterman, Jeffrey M., Martell, Robert E., Carducci, Michael A.
Argitaratua 2008

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

nork Garcia-Manero, Guillermo, Assouline, Sarit, Cortes, Jorge, Estrov, Zeev, Kantarjian, Hagop, Yang, Hui, Newsome, Willie M., Miller, Wilson H., Rousseau, Caroline, Kalita, Ann, Bonfils, Claire, Dubay, Marja, Patterson, Tracy-Ann, Li, Zuomei, Besterman, Jeffrey M., Reid, Gregory, Laille, Eric, Martell, Robert E., Minden, Mark
Argitaratua 2008